论文部分内容阅读
为了评估32mg纳曲酮缓释片/360mg安非他酮缓释片(NB)在有和没有服用口服降血糖药物的超重/肥胖2型糖尿病患者中的有效性和安全性,来自美国德克萨斯州贝勒医学中心的Priscilla Hollander教授及其团队进行了一项56周的双盲安慰剂对照研究,505例接受规范化生活方式干预的患者按2:1随机分到NB组或安慰机组。复合主要终点为体重变化百分比和体重下降≥5%。次要终点包括HbA1c<7%,体重下降≥10%和HbA1c、腰
In order to evaluate the efficacy and safety of 32 mg naltrexone sustained release tablets / 360 mg bupropion sustained release tablets (NB) in overweight / obese type 2 diabetic patients with and without oral hypoglycemic agents, Priscilla Hollander, Baylor Medical Center, Sahs, and his team conducted a double-blind, placebo-controlled study of 56 weeks in which 505 patients undergoing standardized lifestyle intervention were randomized to NB or placebo at a 2: 1 ratio. The composite primary end point was a percentage change in body weight and weight loss ≥5%. Secondary end points included HbA1c <7%, weight loss ≥ 10% and HbA1c, waist